$AVTR

Avantor, Inc.

Avantor provides products and services to customers in biopharma and healthcare, education and government, and advanced technologies and applied materials. It operates through two segments, Laboratory Solutions and Bioscience Production, and goes to market through VWR, its laboratory consumables and equipment distribution channel, and specialty manufacturing. Its offerings include materials and consumables, equipment and instrumentation, and services such as procurement, logistics, laboratory support, and biopharmaceutical scale-up and development. Avantor makes proprietary products including J.T. Baker high-purity chemicals, Masterflex fluid-handling products, and NuSil high-purity silicone for human implants, and distributes products from third-party suppliers. Its VWR channel offers products under the VWR label as well as products from suppliers. Avantor serves more than 300,000 customer locations in approximately 180 countries. It is headquartered in Radnor, Pennsylvania.

AlphAI earnings readThird Quarter 2026 · OCT 28Avantor® Reports Third Quarter 2026 ResultsVerdict: solid

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

No enriched coverage for $AVTR in the last 7 days.

No SEC Form 4 filings for $AVTR in the last 30 days.

See all $AVTR insider activity →
Low

Avantor, Inc. (AVTR): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Avantor, Inc. (AVTR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 30, 2026, the Compensation and Human Resources Committee (the “Committee”) of the Board of Directors of Avantor

Avantor® Reports Third Quarter 2026 Results

Avantor (NYSE: AVTR) reported Q3 2026 net sales of $1.7B, up 4.6% YoY, with organic growth of 5.2%. GAAP EPS was $0.30, and adjusted EPS was $0.22. The company raised FY 2026 guidance for organic revenue growth, adjusted EPS, and free cash flow. VWR Distribution & Services saw 5.8% organic growth, while Bioscience & Medtech Products returned to organic growth at 3.6%.

AVTR sentiment & insider activity

Recent AVTR coverage spans earnings, corporate actions and financial news.

What's driving AVTR

AlphAI scores every news story that mentions AVTR with an AI model for sentiment and relevance, and aggregates insider trades from Avantor, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $AVTR

Score

Avantor, Inc. (AVTR): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Avantor, Inc. (AVTR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 30, 2026, the Compensation and Human Resources Committee (the “Committee”) of the Board of Directors of Avantor

$AVTRHighAI 8/10

Avantor® Reports Third Quarter 2026 Results

Avantor (NYSE: AVTR) reported Q3 2026 net sales of $1.7B, up 4.6% YoY, with organic growth of 5.2%. GAAP EPS was $0.30, and adjusted EPS was $0.22. The company raised FY 2026 guidance for organic revenue growth, adjusted EPS, and free cash flow. VWR Distribution & Services saw 5.8% organic growth, while Bioscience & Medtech Products returned to organic growth at 3.6%.

Avantor (AVTR) is Regaining Market Confidence

Longleaf Partners Fund's Q3 2026 letter notes Avantor (AVTR) stock rose over 50% due to market confidence in its growth and turnaround plan. AVTR's VWR business returned to organic growth, while Bioprocessing showed order improvements. The firm trimmed its position as the stock neared its value target. AVTR closed at $16.62 with a $11.24B market cap, posting a 45.03% YTD pullback.

$AVTRMedExec change· appointed

Avantor, Inc. (AVTR): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Avantor, Inc. (AVTR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EXHIBIT 99.1 NEWS RELEASE FOR IMMEDIATE RELEASE Avantor appoints new Chief Financial Officer RADNOR, Pa. – September 21, 2026 – Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technolog

$AVTRMedExec change· appointed

Avantor, Inc. (AVTR): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Avantor, Inc. (AVTR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 21, 2026, Avantor, Inc. (the “Company”), announced the appointment of Todd Garner as Executive Vice President

Avantor (AVTR) Raises Guidance, Is The Stock Already Overvalued?

Avantor (AVTR) raised its full-year revenue and earnings guidance after Q2 2026 results, despite noting softness in Bioscience & Medtech Products. The stock has seen a 15.6% 30-day gain and 62.9% 90-day gain, but long-term returns remain negative. Analysts' consensus price target is $14.56, suggesting a 7% overvaluation, with targets ranging from $12.0 to $19.0. The P/S ratio is 1.6x, lower than industry and peer averages.

$BRKRHighAI 8/10

Research Tools & Consumables Stocks Q2 Highlights: Bruker (NASDAQ:BRKR)

Bruker (BRKR) reported Q2 revenue of $838.5M, up 5.2% YoY but missing estimates by 1.9%. Its stock fell 7.3% post-results. Avantor (AVTR) beat expectations with $1.69B revenue, up flat YoY, and its stock rose 17.1%. Waters (WAT) saw 113% revenue growth but mixed guidance, with its stock up 10.3%. Bio-Techne (TECH) and Danaher (DHR) also reported earnings, with TECH flat and DHR up 5.7% post-results.

Related tickers